Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Research team creates human ALS motor neurons

A team of researchers from the Harvard Stem Cell Institute (HSCI) and Columbia University, in a collaboration catalyzed by the Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, has demonstrated that pluripotent stem cells generated from a patient with ALS (amyotrophic lateral sclerosis) can be directed to differentiate into motor neurons - the very brain cells destroyed by ALS.

31 Jul 2008

Researchers find key mechanism of cell damage in aging and disease

Researchers have taken a first snapshot of how a class of highly reactive molecules inflicts cellular damage as part of aging, heart disease, stroke, cancer, diabetes, kidney disease and Alzheimer's disease to name a few. According to a study published today in the journal Cell, researchers have discovered a tool that can monitor related damage and determine the degree to which antioxidant drugs effectively combat disease.

24 Jul 2008

Open access to large-scale drug discovery data

The Wellcome Trust has awarded £4.7 million (€5.8 million) to EMBL's European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from publicly listed company Galapagos NV to the public domain.

23 Jul 2008

EpiCept and GNI partner to develop anti-viral hepatitis drug in Asia

GNI Ltd and EpiCept Corporation have announced that they have reached agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-IND and clinical development in China immediately.

17 Jul 2008

New technology revolutionizing drug discovery

The National Science Foundation has awarded Weill Cornell Medical College researcher Dr. Scott Blanchard its prestigious Career Award, recognizing his groundbreaking work in cell biology -- work that is poised to revolutionize research for the next generation of young scientists.

15 Jul 2008

New center for protein therapeutics formed by UB pharmaceutical scientists

Pharmaceutical researchers at the University at Buffalo have joined forces with scientists from several of the world's largest pharmaceutical companies to tackle fundamental research questions that need to be answered to advance development of promising protein-based drugs.

15 Jul 2008

Eli Lilly to buy SGX Pharmaceuticals

Eli Lilly and Company and SGX Pharmaceuticals, Inc. today announced that the companies have signed a definitive merger agreement providing for the acquisition of SGX in an all-cash transaction. SGX, based in San Diego, California, is a biotechnology company focused on drug discovery and development in the area of oncology.

8 Jul 2008

Clinical Data secures European patent for key multi-drug resistance gene

Clinical Data, Inc. has announced that the European Patent Office has granted Patent No. 1232260 to Bernried, Germany-based Epidauros Biotechnologie AG, a wholly-owned subsidiary of Clinical Data, relating to the use of a genetic variant, or biomarker, of the gene MDR1 (also known as ABCB1), which encodes P-glycoprotein (PGP).

26 Jun 2008

VistaGen Therapeutics announces new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells

VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, has announced new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells. VistaGen has exclusive rights for commercial use in its ES Cell-based tools platform for drug discovery and development.

16 Jun 2008

New technique provides greater understanding of how drugs get in and out of cells in our bodies

A team led by female scientists at the Universities of Bristol and Cambridge has developed an exciting new technique which may lead to a greater understanding of how drugs get in and out of the cells in our bodies. The method identifies the structures that guard the entrance and exits to cells.

15 Jun 2008

Researchers find gamma-secretase modulators being tested for Alzheimer’s work in unexpected and beneficial ways

Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.

11 Jun 2008

GlaxoSmithKline Acquires Sirtris Pharmaceuticals

GlaxoSmithKline has announced that it has completed its acquisition of Sirtris Pharmaceuticals, Inc. (Sirtris) for approximately USD720 million (or approx. GBP362 million) through a cash tender offer and merger of USD22.50 (or approx. GBP11.33) per share.

8 Jun 2008

Prostate Cancer Foundation 'beefs up' cancer research

The Prostate Cancer Foundation (PCF) has committed more than $19 million in new research funding for scientific investigations focused on discovering new treatments for recurrent prostate cancer. A total of eight programs representing 18 leading research institutions and 36 researchers were selected as part of the foundation's 2008 Challenge Awards. The funded programs will receive the first of three annual payments, ranging between $500,000 and $1.0 million per program, this week.

4 Jun 2008

Soil bacteria may offer potential treatments for MRSA and cancer

Big pharma gave up on soil bacteria as a source of antibiotics too soon, according to research published in the June issue of Microbiology. Scientists have been mining microbial genomes for new natural products that may have applications in the treatment of MRSA and cancer and have made some exciting discoveries.

1 Jun 2008

Global drug research programme comes to Diamond in Oxfordshire

Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source

27 May 2008

Scripps Research Institute awarded patent for revolutionary technology

The Scripps Research Institute has been awarded U.S. Patent No. US 7,375,234 B2, which covers a broad class of chemical reactions that mimic biological efficiency and opens the door to a new world of chemistry.

20 May 2008

Cytopia announces novel anti-cancer drug development collaboration

Cytopia Limited today announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest growing segments of the cancer drug market.

9 May 2008

Silent fungus metabolism awakened for source of new drugs

U.S. scientists have re-awakened 'silent' metabolic pathways in fungi to reveal a new range of natural products. The research could provide not only a source of new drugs, but a way to "listen to what fungi are saying" to organisms around them.

30 Apr 2008

New drug discovery tool for Alzheimer's disease

An article published in the April issue of the Journal of Alzheimer's Disease presents a detailed characterization of a new drug discovery tool for Alzheimer's disease.

28 Apr 2008

Biopharmaceutical spin-out company Domainex, secures funding

Headquartered in London, Domainex is a contract research company specialising in the provision of structural biology and chemistry services to major pharmaceutical and biotechnology firms. The Company is also developing a pipeline of pre-clinical drugs and targets.

From Domainex 23 Apr 2008